“…Among them ADI is one of the most important and best characterized enzymic drugs. The earlier application of ADI is focused against the treatment of hepatocellular carcinomas but in the recent past, scientific community trying to search new therapeutic applications of ADI in treatment of other arginine auxotrophic tumors such as pancreatic cancer (Liu et al, 2014), prostate cancer (Changou et al, 2014), leukemia (Miraki-Moud et al, 2015), colon cancer (El-Sayed et al, 2015), and breast cancer (Li et al, 2016). As we know that, ADI is a significant player of ADI or arginine dihydrolase (ADH) pathway and generating one molecule of ATP by phosphorylation of ADP.…”